Related content

Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer

By Gordon A.N.   Hancock K.C.   Matthews C.M.   Messing M.   Stringer C.A.   Doherty M.G.   Teneriello M.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 129-135

Elsevier

Access to resources Recommend Favorite

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 673-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin

By Choi Chel   Kim Min   Park Jin-Young   Yoon Aera   Kim Ha-Jeong   Lee Yoo-Young   Kim Tae-Joong   Lee Jeong-Won   Kim Byoung-Gie   Bae Duk-Soo  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1181-1187

Springer Publishing Company

Access to resources Recommend Favorite

Results of Reinduction Therapy with Paclitaxel and Carboplatin in Recurrent Epithelial Ovarian Cancer

By Gronlund B.   Hogdall C.   Hansen H.H.   Engelholm S.A.  

Gynecologic Oncology, Vol. 83, Iss. 1, 2001-10 ,pp. : 128-134

Elsevier

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite